Introduction
Pseudobulbar Affect (PBA) is an affect disinhibition syndrome characterized by uncontrollable, exaggerated, and often inappropriate outbursts of crying or laughing (Schiffer and Pope, 2005) . It has been associated with disruption or damage to neural systems that modulate voluntary and involuntary emotional expression (Wortzel et al., 2008; Parvizi et al., 2009; Lauterbach et al., 2013) . PBA has been identified in patients with a multitude of neurological disorders, including traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, and Alzheimer's disease (Moore et al., 1997; Schiffer and Pope, 2005; Wortzel et al., 2008; Parvizi et al., 2009; Colamonico et al., 2012) . TBI is common in military service members deployed in support of Operation Enduring Freedom, Operation Iraqi Freedom, and Operation New Dawn (OEF/OIF/OND), occurring in 10-23% of returning Veterans; the majority of TBI injuries are mild in severity (Hoge et al., 2008; Terrio et al., 2009; Cifu et al., 2013) . In a survey that formed the basis for the present study, we identified PBA symptoms in 70% (n ¼513) of OEF/OIF/OND Veteran respondents who screened positive for TBI .
TBI represents a well-recognized threat to mental well-being and health of Veterans. Veterans with TBI are more prone to pain syndromes, sleep disorders, and other mental health conditions, particularly posttraumatic stress disorder (PTSD) and depression (Lippa et al., 2015) . PBA may further add to the mental health burden . Additionally, Veterans with co-morbid TBI, PTSD, and depression reported substantially worse functioning compared to Veterans with single or pairwise combinations of these conditions (Lippa SM et al., 2015) .
PTSD occurs in 12-30% of OEF/OIF/OND service members and Veterans (Seal et al., 2009; Thomas et al., 2010; Higgins et al., 2014) . The co-occurrence of TBI and PTSD is much more common than TBI alone (Lippa SM et al., 2015) , and PTSD is more prevalent and severe among Veterans who sustain a TBI (Hoge et al., 2008; Schneiderman et al., 2008) . Because PTSD affects some of the same neural systems as traumatic brain injury (TBI) (Stein and McAllister, 2009) , it is possible that the co-occurrence of TBI with PTSD may exacerbate PBA symptoms. As a result, when studying TBI within the Veteran population, the potential influence of comorbid PTSD must be considered.
The purpose of this study was to examine the relationship of PBA symptom frequency and severity to health-related quality of life and health system costs in Veterans with confirmed TBI, stratified by PTSD diagnosis. We hypothesized that increased PBA symptoms would be associated with reduced quality of life and increased medical costs in Veterans with TBI, and that these effects would be present irrespective of comorbid PTSD. We identified patients with TBI based on the Veterans Administration (VA) TBI electronic screening mechanism and surveyed patients with known TBI to assess quality of life and PBA symptoms. Clinical characteristics and healthcare utilization and cost were obtained from the Veterans Health Administration (VHA) electronic medical records.
Methods

Study population
Our study population consisted of OEF/OIF/OND Veterans in the New England region (VISN-1) who had a confirmed deploymentrelated TBI on the VHA comprehensive TBI evaluation between April 2007 and April 2013. Clinical and healthcare utilization records and VHA electronic medical records, including inpatient hospitalization admissions and clinic visits, were linked for qualifying Veterans for fiscal year 2012 (the study period). We excluded Veterans if they had a prior diagnosis of bipolar disorder, schizophrenia, or other major psychiatric disorder recorded in the VA medical record. Veterans with trauma-related hallucinations were retained in the study.
Procedure
Four thousand two hundred and eighty two (4282) Veterans in our study population who had a positive TBI screen were mailed a packet that included a cover letter, a survey, and a pre-addressed, postage-paid return envelope. Our methods have been previously described . Briefly, the patient survey consisted of the Center for Neurologic Study-Lability Scale (CNS-LS), a sevenitem instrument that assesses the frequency and severity of involuntary or excessive laughing and crying symptoms (Moore et al., 1997) , and the EuroQol -Five Dimensions -Five Levels (EQ-5D-5L) (Rabin et al., 2011) , a five-item survey questionnaire that assesses health-related quality of life. Among 3954 Veterans (92%) with accurate mailing addresses, 758 (19%) completed the survey. Among these, 210 with clinically confirmed TBI made up the study population. A previous report of this sample showed that, compared to survey non-respondents, respondents (n ¼758) were more likely to be older, white, married, and college graduates, and to have a higher prevalence of depression, prescriptions for depression, and arthropathy related pain . Respondents were similar to non-respondents for all other comorbid conditions and biomedical characteristics, including PTSD, anxiety disorders, substance abuse, and headaches/migraines. Baseline demographic and clinical characteristics and healthcare utilization and cost were obtained from the VHA electronic medical records. Outpatient visits and hospitalizations, including diagnosis codes, were extracted from the National Patient Care Database (NPCD). Pharmacy and cost data were extracted from the VA Decision Support System (DSS). The survey data were linked to the VA files using a unique identifier. The survey cover letter included all elements of informed consent, and completion and return of the questionnaire was considered implied consent. All procedures were approved by the VA Boston Institutional Review Board.
Measures
PBA symptom frequency/severity
We assessed the presence of PBA symptoms using the CNS-LS. The seven-item CNS-LS is a quantitative measure of the frequency and severity of PBA symptoms (range 7-35; higher is worse symptoms) (Moore et al., 1997; Smith et al., 2004) . In validation studies, a score of Z13 best predicted a physician diagnosis of PBA in patients with ALS (Moore et al., 1997 ) and a score Z17 best predicted a physician diagnosis of PBA in patients with MS (Smith et al., 2004) . For this analysis, PBA symptom frequency/severity was categorized as: low (CNS-LS o13), mild (CNS-LS 13-20), and moderate-severe (CNS-LS Z21) (Moore et al., 1997; Colamonico et al., 2012; Brooks et al., 2013) .
Prescription medications
We determined use of medication based on having at least one prescription filled during fiscal year 2012. Medication classes evaluated included antidepressants, opioids, sedative/hypnotics, antiepileptics, antilipemic agents, and antihypertensives.
Comorbid conditions
The presence of a current mental health disorder, including major depressive disorder, PTSD, anxiety disorders, and alcohol and substance abuse disorders, as well as pain conditions were determined using International Classification of Diseases, Ninth Revision (ICD-9) diagnostic codes. We considered a diagnosis to be current if the Veteran had one or more diagnosis codes or received a prescription for an agent to treat the conditions of interest during fiscal year 2012.
Health-Related Quality of Life
We measured health-related quality of life using the EQ-5D-5L questionnaire, which is an international, standardized, generic measure of health status developed by the EuroQol Group (Rabin et al., 2011) . The EQ-5D-5L is a two-part instrument consisting of five health status dimensions (i.e., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a visual analog scale (VAS). Each health status dimension is rated using a fivelevel scale (range 1-5, with 1 ¼no problems and 5¼ extreme problems/inability to perform activity). The information from the dimensions was also combined into an EQ-5D index score using weights from United States standard population values (Rabin et al., 2011 ) (range 0-1, lower is worse). The VAS represents the self-reported health status of the Veteran (range 0-100, lower scores indicate poorer health status). We calculated the mean and standard deviation (SD) for the VAS and index scores.
Healthcare utilization and cost
Healthcare utilization was captured by the unique number of claims, including inpatient hospitalization admissions and clinic visits, for each Veteran during fiscal year 2012. We calculated the median number of claims and the interquartile range (IQR). Variable direct costs, which include the cost of supplies and labor based on the volume of services, were chosen as opposed to total costs because the VA has significant fixed costs that are unrelated to the cost directly attributable to patient care (i.e., research service). Participants without a VHA claim during fiscal year 2012 were assigned a zero variable direct cost. We calculated descriptive statistics for the variable direct costs, including mean, SD, median, and IQR.
Statistical analyses
We summarized the demographic and clinical characteristics for the sample, both overall and stratified by PBA symptom frequency/severity. For categorical variables, statistical significance of differences between groups was determined using Fischer's exact test (α ¼0.05).
The remaining analyses were stratified by PTSD diagnosis to examine the effect(s) of TBI alone versus TBI with co-occurring PTSD. EQ-5D-5L health status was determined for the overall health scores and each of the five dimensions. For categorical variables, we tested statistical significance between strata using the Fisher's exact test. Analysis of variance (ANOVA) was used to determine if there was a significant interaction between the severities of PBA symptoms (low, mild, moderate-severe) and PTSD diagnosis (no, yes) for the overall health status measures, with a separate model for VAS and EQ-5D-5L index scores. For the health status dimensions, we calculated the mean and SD of the responses (1-5 for each dimension), as well as the frequency and percent of Veterans with moderate or worse impairment (moderate-severe problem or unable to perform; 3 or greater on 1-5 scale). Log-linear models were used to identify significant interactions between the severity of PBA symptoms (low, mild, moderate-severe) and PTSD diagnosis, and the EQ-5D-5L dimension responses (dichotomized to less than moderate and moderate or greater impairment) (Agresti, 2002) .
Analyses were conducted using SAS (version 9.3) software and R (version 3.0.0).
Results
Our study population (n¼ 210) was predominantly male (95%), with an average age of 37.8 years (SD ¼ 9.78). Based on reported CNS-LS scores, 27.1% (n ¼57) of respondents had no PBA symptoms, 44.3% (n ¼93) had mild PBA symptoms, and 27.6% (n ¼ 60) had moderate-severe PBA symptoms (Table 1) . Age, sex, education level, and diagnosed physical comorbidities, including pain conditions, were not statistically different across the PBA symptom frequency/severity categories. The overall prevalence of a PTSD diagnosis was 53%, and significantly increased with PBA symptom frequency/severity: low (n ¼21, 36.8%), mild (n ¼49, 52.7%), and moderate-severe (n ¼42, 70%) (p¼ 0.0015). Similarly, anxiety disorder (17% overall) increased significantly with PBA symptom frequency/severity: low (n ¼2, 3.5%), mild (n ¼ 20, 21.5%), and moderate-severe (n ¼14, 23%) (p ¼0.0021). Major depression increased similarly, but not significantly. The prevalence of prescription medications for mental health issues followed the same increasing trend, with all but opioids showing statistically significant differences across PBA symptom frequency/severity categories.
Overall health status decreased with increasing PBA symptom frequency/severity, as shown in Table 2 . ANOVA revealed a main effect of PBA symptom frequency/severity on mean EQ-5D-5L VAS (F¼ 9.73; df ¼ 2, po 0.0001) and index scores (F¼13.84; df ¼2, p o0.0001) for the entire population. However, there was no statistically significant interaction between PBA symptom frequency/ severity and PTSD diagnosis for either mean EQ-5D-5L VAS (F¼0.20; df ¼2, p ¼0.820) or EQ-5D-5L index scores (F¼1.44; df ¼ 2, p¼ 0.239). The log-linear models for the five health status dimensions showed significant associations with PBA symptoms (mild/moderate-severe vs. low) independent of PTSD status in three dimensions: pain/discomfort (odds ratio [OR] ¼ 3.6; 95% confidence interval [CI]: 1.5,8.6), usual activities (OR ¼3.5; 95% CI: 1.6, 7.8), and anxiety/depression (OR ¼ 13.5; 95%CI: 4.3, 42.2).
Tables 3 and 4 describe the healthcare utilization and variable direct cost outcomes according to PBA symptom frequency/severity and the presence or absence of PTSD. Mean total and outpatient costs were highest in those with moderate-severe PBA symptoms and PTSD. Mean total health costs in those with mild and moderate-severe PBA symptoms were 32% and 102% higher, respectively, than in those with low PBA symptom (Table 3) , although SDs were large compared to the mean values. In those with comorbid PTSD, costs were only modestly higher (8.6%) in those with moderate-severe PBA symptoms compared to low PBA symptoms. Costs for those with PTSD were three-to six-fold higher within PBA symptom frequency/severity categories compared to those without PTSD (Table 4) . Mental health costs made up about 20-30% of outpatient healthcare costs in five of the six PBA by PTSD strata (data not shown); however for the stratum with "moderate-severe PBA symptoms and no PTSD," mental health costs made up only 7% of outpatient costs. This stratum was very small (n ¼4) and the relative SD was large (SD/mean ¼2.95). Regardless of PTSD diagnosis, the relative increases in costs were larger between the low and mild PBA symptom groups than between the mild and moderate-severe PBA symptom groups.
Discussion
This study of Veterans with TBI, who were surveyed about PBA symptoms and quality of life, found that the severity of PBA symptoms was associated with presence of a PTSD diagnosis, increased use of prescription medications, and decreased quality of life across a number of dimensions. PBA symptoms were associated with decreased quality of life, particularly in the pain/discomfort, usual activities, and anxiety/depression dimensions, independent of PTSD diagnosis. Additionally, the mean total outpatient costs increased with increasing PBA symptoms. These results suggest that in patients with TBI, an assessment of PBA symptoms may identify patients who report lower quality of life and accrue more healthcare costs.
The two metrics of overall health-related quality of life (VAS and EQ-5D) declined significantly as a function of PBA symptom Table 2 Quality of life by current PTSD diagnosis and PBA symptom frequency/severity. Abbreviations: CNS-LS, Center for Neurologic Study-Lability Scale; EQ-5D, EuroQol -Five Dimensions; VAS, visual analog scale. Note: the mean (SD) were calculated for the VAS score, EQ-5D index score, and functioning total for each quality of life domain. VAS score ranged from 0-100. EQ-5D index score ranged from 0-1 and was computed using weights from the United States standard population values. Moderate or greater impairment was defined as a functioning score of 3 or greater for each health status domain. frequency/severity, regardless of the highly comorbid condition of PTSD. This suggests that the involuntary expression of emotion characteristic of PBA symptoms following TBI may not be an expression of emotional disinhibition that can be characteristic of PTSD, but rather that PBA symptoms may be an independent factor of the decline in quality of life. This adds to the complexity of the clinical presentation of these Veterans, and our analysis of the quality of life dimensions provides further insight into the underlying mental health challenges. Our findings of decreasing quality of life in the anxiety/depression, pain/discomfort, and usual activities dimensions (independent of PTSD) underscore the functional challenges patients with increasing PBA symptoms confront. The association of increasing EQ-5D anxiety/depression scores with increasing PBA symptoms is consistent with previous studies that reported increased depression (Phuong et al., 2009; Colamonico et al., 2012) and/or anxiety (Tateno et al., 2004; Colamonico et al., 2012) in subjects reporting PBA symptoms. While not assessing PBA specifically, our prior work (Lippa et al., 2015) found that pain/discomfort was related to TBI, perhaps due to the high prevalence of blast injuries in the OEF/OIF/OND cohort that can affect multiple biological systems (i.e., central nervous system, pulmonary, musculoskeletal). The association of the increasing EQ-5D usual activity scores (poorer function) with increasing PBA symptoms is consistent with previous studies that reported significantly poorer function on activities of daily living scales (Colamonico et al., 2012) , social functioning scales (Tateno et al., 2004) , and a general quality of life measure. a (Brooks et al., 2013) Lastly, we found that patients with the most severe PBA symptoms accrued higher costs, in particular, outpatient costs. While there was an overall three-to four-fold increase in costs for those with PTSD, there was a consistent increase in outpatient costs associated with increasing PBA symptoms. Past work has found that treatment decisions were based on the more commonly recognized and diagnosed comorbid mental health conditions rather than recognized PBA even when PBA is present, and perhaps, misdiagnosed (Arciniegas et al., 2005 , Engelman et al., 2014 .
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While our data suggest that there may be an association between PBA severity and TBI severity (not reported), we do not feel that the current data can support this claim definitively, as our instrument identified only a handful of participants with moderate or severe TBI (n ¼22). Further exploration of this possibility is warranted in future investigations.
This study has strengths that should be recognized. First, the study included patients with known TBI, and particularly those with mild TBI. The population studied had more mental health conditions than the general US population of similar age. We found prevalences of diagnosed major depression, PTSD, and anxiety disorders of 32.4%, 53.3%, and 17.1%, respectively. In the National Comorbidity Survey Replication, reported prevalences of major depression, PTSD, and anxiety in 30-to 44-year-olds were 19.8%, 8.2%, and 6.8%, respectively (Kessler et al., 2005) . The study population had access to and was receiving mental health treatments as demonstrated by VA cost, claims, and pharmacy data, which developed a comprehensive picture of healthcare utilization by these Veterans.
There are also limitations to this work. First, the study utilized a home survey tool to identify PBA symptoms. As a result, we were unable to determine the circumstances of the survey completion. While this PBA symptom scale has good sensitivity and specificity relative to physician diagnosis of PBA in persons with ALS and MS, its diagnostic utility has not been specifically validated in TBI. Additionally, we utilized claims data to determine those with and without PTSD. Clearly, the work would have benefitted from a clinical diagnosis of PBA and documented diagnosis of PTSD. Additionally, the Veteran population tends to be predominantly male, and in this case, younger. In the current sample, there were only nine females, which precluded our ability to examine gender differences in the incidence of PBA following TBI. Our study sample was defined to determine whether PBA symptoms are present in a Veteran cohort with a history of military TBI. The Veteran cohort is predominantly male; more so among those exposed to combat who would have heightened risk for TBI, and this was reflected in our final sample. Only about 8% of the Veteran population is female and females represent less than 4% of Veterans who have served in war zones (Boyd et al., 2013) . A subsequent study that oversamples women with TBI would be required to address gender differences in PBA following TBI.
The current, cross sectional data revealed high co-prevalence of TBI, PBA and PTSD. While we presume the progression begins with TBI (and PBA by definition occurs as a consequence of neurologic injury), we cannot confirm that with these data. Understanding the relationship(s) between physical trauma to the brain and the development of psychological sequelae of trauma is currently a focus of much research. Advancement of our knowledge of these relationships will require longitudinal studies that can track the a The quality of life measure rated the response to the question, "How has your neurological condition affected your quality of life?" on a horizontal, 11-point integer scale ranging from 0 (not at all) on the left to 10 (strongly affected) on the right.
progression and development of illness overtime. However, this study was able to minimize potential retrospective reporting biases common to cross-sectional studies by obtaining clinical and TBI information from electronic medical records and standardized TBI reports. Finally, this study limited the sample to OEF/OIF/OND Veterans who received care at a VA in the New England region. Nevertheless, this sample closely resembles the demographic characteristics of a national cohort of younger US Veterans and survey non-respondents (Eber et al., 2013; Fonda et al., 2015) . Thus, results could be generalized to a national sample of OEF/OIF/ OND Veterans with deployment-related TBI.
Conclusion
This study examined the relationship of PBA symptom frequency/severity to health-related quality of life and outpatient costs in OEF/OIF/OND Veterans in the New England region with mild TBI. We found that severe PBA symptoms were associated with reduced quality of life and increased outpatient medical costs in those with and without comorbid PTSD.
Patients with TBI should be assessed for the presence of PBA symptoms. The larger survey that preceded this work, , found that simply asking a single question about the presence of involuntary or exaggerated episodes of laughing or crying may be an effective means of determining the need for further assessment. Veterans who screen positive for PBA symptoms using this single question could undergo a more thorough clinical evaluation, including the use of the CNS-LS to evaluate the frequency and severity the PBA symptoms.
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